Search for: "MALLINCKRODT BAKER, INC."
Results 1 - 1
of 1
Sorted by Relevance
|
Sort by Date
1 Dec 2017, 11:35 am
Paganini will complement OncoResponse, since OncoResponse has a strong focus on antibody cancer drugs and Paganini recently developed ONCR-201, a monoclonal antibody used in treating ovarian cancer.[29] Mallinckrodt PLC is expected to purchase Ocera Therapeutics Inc. in addition to its mid-stage hepatic encephalopathy, for about $42 million and to close in the fourth quarter of 2017. [read post]
